JAN AUSHADHI KOTTIYAM PRICE RS 210 FOR 10 TAB
Tolvaptan is an aquaretic drug that functions as a
selective, competitive vasopressin receptor 2 (V2) antagonist used to treat
hyponatremia (low blood sodium levels) associated with congestive heart
failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone
(SIADH). Tolvaptan was approved by the U.S. Food and Drug Administration (FDA)
on May 19, 2009. Tolvaptan, as Jynarque, was granted approval for medical use
in the United States in April 2018.
The U.S. Food and Drug Administration (FDA) granted
tolvaptan a fast track designation for clinical trials investigating its use
for the treatment of polycystic kidney disease. The FDA granted Jynarque an
orphan drug designation in April 2012, for the treatment of autosomal dominant
polycystic kidney disease.
Tolvaptan is
available as a generic medication.
C26H25ClN2O3
Use
Tolvaptan (Samsca) is indicated for the treatment of
clinically significant hypervolemic and euvolemic hyponatremia.
Tolvaptan (Jynarque) is indicated to slow kidney function
decline in adults at risk of rapidly progressing autosomal dominant polycystic
kidney disease (ADPKD).
Side effects
The FDA has determined that tolvaptan should not be used for
longer than 30 days and should not be used in patients with underlying liver
disease because it can cause liver injury, potentially leading to liver
failure. When using to treat hyponatremia, it may cause too rapid correction of
hyponatremia resulting in fatal osmotic demyelination syndrome.